Eli Lilly shares surge on a beat-and-raise, proving the stock's swoon was a mistake
Eli Lilly's shares rose significantly following a strong earnings report that exceeded expectations and included an upward revision to full-year guidance, signaling renewed investor confidence. The positive market reaction suggests that recent declines in the stock may have been unwarranted. The performance was driven by robust demand for its diabetes and obesity drugs, particularly Mounjaro and Zepbound.
Opening excerpt (first ~120 words) tap to expand
Subscribe to CNBC PROSubscribe to Investing ClubLicensing & ReprintsCNBC CouncilsSelect Personal FinanceJoin the CNBC PanelClosed CaptioningDigital ProductsNews ReleasesInternshipsCorrectionsAbout CNBCSite MapPodcastsCareersHelpContactNews TipsGot a confidential news tip? We want to hear from you.Get In TouchCNBC NewslettersSign up for free newsletters and get more CNBC delivered to your inboxSign Up NowGet this delivered to your inbox, and more info about our products and services.Advertise With UsPlease Contact UsAd ChoicesPrivacy PolicyYour Privacy ChoicesCA NoticeTerms of Service© 2026 Versant Media, LLC. All Rights Reserved. A Versant Media Company. Data is a real-time snapshot *Data is delayed at least 15 minutes.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at CNBC — Top.
Discussion
0 commentsMore from CNBC — Top
